Estancia La Jolla Hotel
La Jolla, California


SYMPOSIUM INFORMATION

>General Information
>Faculty
>Program/Schedule
>Accreditation
>Registration
>Hotel Reservations

 

Sponsored by:

UC San Diego Sulpizio Cardiovascular Center

Endorsed by:
The Heart Failure Society of America



American College of Cardiology



California Chapter

 

PROGRAM / SCHEDULE

7:00 – 8:00am Registration/Coffee

7:00-8:00am
Product Theatre Breakfast (Non-CME) - Support provided by Janssen
XARELTO® Pivitol Trials and Recently Published Real World Evidence in
NVAF – Including Patients with NVAF and Heart Failure
Uri Elkayam

8:05-8:15am
Introductions, Welcome and Overview
Drs. Alan Maisel and Lori Daniels

SESSION I
Heart Failure
Alan Maisel, MD, (Moderator)

8:15-8:30am
Guiding Therapy in Heart Failure - Alan Maisel, MD

8:30-8:45am
State of the Art Treatment - Hyponatremia, Heart Rate, et al
Uri Elkayam, MD

8:45- 9:15am
Robert Jesse Memorial Lecture
The Legacy of Bob Jesse
Allan Jaffe, MD

9:15-9:30am
Heart Failure Diagnosis - New Biomarkers and Devices
Nicholas Wettersten, MD

9:30-9:45am
Incorporating a Pulmonary Artery Device and Biomarkers in
Outpatients with Heart Failure
Brian Jaski, MD

9:45-10:00am
Potassium and Sodium as Treatable Biomarkers in Cardiovascular Disease:
Hyperkalemia and Hyponatremia
J. Thomas Heywood, MD

10:00-10:15am
Advanced Therapies in Heart Failure - Impella, LVAD and Beyond
Eric Adler, MD

10:15-10:45am Break/Visit Exhibits

SESSION II
Ischemia
Lori Daniels, MD (Moderator)

10:45-11:25am
DEBATE
Highly Sensitive Cardiac Troponin - A Must-Have for All of Us?
Lori Daniels, MD (Moderator)

    10:50-11:00am PRO: hsTn Should be Embraced by All - Frank Peacock, MD

    11:00-11:10am CON: hsTn is Unwelcome Here - James deLemos, MD

    11:10-11:15am PRO: Rebuttal - Frank Peacock, MD

    11:15-11:20am CON: Rebuttal - James deLemos, MD

    11:20-11:25am Debate Conclusion/Q&A - Lori Daniels, MD

11:25-11:45am
State of the Art - Optimal Use of hsTn in the US
Lori Daniels, MD

11:45-12:05pm
Case Presentations and Panel
Lori Daniels, MD (Moderator)

12:05-1:35pm Lunch

SESSION III
Diabetes, Kidneys, and Heart Disease – What’s New in Biomarkers?
Lori Daniels, MD (Moderator)

1:35-1:50pm
PCSK9 Inhibitors and Modulators
Pam Taub, MD

1:50-2:05pm
Cardiologists and HbA1c: Novel Diabetes Drugs and Cardiovascular
Disease Outcomes
Gregg Fonarow, MD

2:05-2:20pm
Biomarkers of Kidney Dysfunction and Cardiorenal Syndrome
Peter McCullough, MD

2:20-2:35pm
Wearable Devices for Heart Disease, Diabetes and Health
Pam Taub, MD

2:35-2:50pm
Metabolomic Predictors of Heart Disease
Mohit Jain, MD, PhD

2:50-3:05pm
Pulmonary Arterial Hypertension: Biomarkers and Treatment
Demos Papamatheakis, MD

3:05-3:35pm Coffee Break/Visit Exhibits

SESSION IV
Biomarkers in Arrhythmias and Beyond
Alan Maisel, MD (Moderator)

3:35-3:50pm
EOL for INR? Part I: Anticoagulation in Atrial Fibrillation, Heart Failure and Cardiovascular Disease
Daniel Blanchard, MD

3:50-4:05pm
EOL for INR? Part II: Alternatives to Anticoagulation in Patients with Atrial Fibrillation
Jonathan Hsu, MD

4:05-4:20pm
Biomarkers and Arrhythmias/Devices
Ulrika Birgersdotter-Green, MD

4:20-4:35pm
Biomarkers in the Age of Sacubitril/Valsartan: Has the PARADIGM Changed?
Alan Maisel, MD

4:35-4:50pm
Concluding Remarks
Alan Maisel, MD and Lori Daniels, MD